Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.31
- Piotroski Score 7.00
- Grade Overweight
- Symbol (AMPH)
- Company Amphastar Pharmaceuticals, Inc.
- Price $45.45
- Changes Percentage (2.02%)
- Change $0.9
- Day Low $44.95
- Day High $45.64
- Year High $65.92
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
- Last Earnings 06/07/2010
- Ex-Dividend for 5/16 Dividend 06/11/2010
- Dividend Payable 06/30/2010
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $66.00
- High Stock Price Target $66.00
- Low Stock Price Target $66.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.91
- Trailing P/E Ratio 13.99
- Forward P/E Ratio 13.99
- P/E Growth 13.99
- Net Income $137.55 M
Income Statement
Quarterly
Annual
Latest News of AMPH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
St. Clair County woman charged after methamphetamine, cocaine seized in drug bust, sheriff says
A 38-year-old woman in St. Clair County faces felony charges for possessing over 80 grams of methamphetamine and other drugs. The woman is charged with multiple drug-related offenses and her bond is s...
By CBS News | 15 hours ago -
Amphenol Corporation (APH) Poised to Benefit from NVIDIA's Blackwell Ramp-Up, Evercore Highlights in AI Industry Note
Amphenol Corporation (NYSE:APH) is compared to other trending AI stocks amid a surge in investment towards AI data centers. Companies like Crusoe Energy are attracting significant funding for building...
By Yahoo! Finance | 1 day ago -
Jim Cramer on Amphenol Corporation (APH): 'I Do Think That This Is A Terrific Stock'
Jim Cramer recently talked about the impact of geopolitical concerns on investor behavior, mentioning a "flight-to-quality" trend where investors turn to safer investments like U.S. Treasury bonds dur...
By Yahoo! Finance | 2 days ago
